

# SAFETY DATA SHEET



AQUATOP 2600-82 - BASE 3

## SECTION 1: Identification of the substance/mixture and of the company/undertaking

### 1.1 Product identifier

**Product name** : AQUATOP 2600-82 - BASE 3

### 1.2 Relevant identified uses of the substance or mixture and uses advised against

**Product use** : Paint.

### 1.3 Details of the supplier of the safety data sheet

Teknos Group Oy, Takkatie 3, FI-00370 HELSINKI, FINLAND. Tel. +358 9 506 091.

**e-mail address of person responsible for this SDS** : Prod-safe@teknos.com

#### National contact

Teknos Group Oy, Takkatie 3, FI-00370 HELSINKI, FINLAND. Tel. +358 9 506 091.

### 1.4 Emergency telephone number

#### National advisory body/Poison Centre

**Telephone number** : Malta Competition and Consumer Affairs Authority (MCCAA): +356 2395 2000

## SECTION 2: Hazards identification

### 2.1 Classification of the substance or mixture

**Product definition** : Mixture

#### Classification according to Regulation (EC) No. 1272/2008 [CLP/GHS]

Not classified.

The product is not classified as hazardous according to Regulation (EC) 1272/2008 as amended.

See Section 11 for more detailed information on health effects and symptoms.

### 2.2 Label elements

**Signal word** : No signal word.

**Hazard statements** : No known significant effects or critical hazards.

#### Precautionary statements

**Prevention** : Not applicable.

**Response** : Not applicable.

**Storage** : Not applicable.

**Disposal** : Not applicable.

**Supplemental label elements** : Contains adipohydrazide, 1,2-benzisothiazol-3(2H)-one, reaction mass of: 5-chloro-2-methyl-4-isothiazolin-3-one [EC no. 247-500-7] and 2-methyl-2H-isothiazol-3-one [EC no. 220-239-6] (3:1), 2-methyl-2H-isothiazol-3-one and 2-Octyl-2H-isothiazol-3-one. May produce an allergic reaction.  
Safety data sheet available on request. Contains biocidal products for in-can preservation: BIT and DTBMA and Bronopol and MIT and OIT and MBIT.

**Annex XVII - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, mixtures and articles** :

## SECTION 2: Hazards identification

### 2.3 Other hazards

**Product meets the criteria for PBT or vPvB according to Regulation (EC) No. 1907/2006, Annex XIII** : This mixture does not contain any substances that are assessed to be a PBT or a vPvB.

**Other hazards which do not result in classification** : None known.

## SECTION 3: Composition/information on ingredients

### 3.2 Mixtures : Mixture

| Product/ingredient name   | Identifiers  | %       | Classification   | Specific Conc. Limits, M-factors and ATEs   | Type |
|---|--|---------|--|---|------|
| Dipropyleneglycolmethylether  | REACH #:<br>01-2119450011-60<br>EC: 252-104-2<br>CAS: 34590-94-8 | ≤3      | Not classified.  | -   | [2]  |
| adipohydrazide  | REACH #:<br>01-2119962900-36<br>EC: 213-999-5<br>CAS: 1071-93-8  | <1      | Skin Sens. 1, H317<br>Aquatic Chronic 2, H411  | -   | [1]  |
| 1,2-benzisothiazol-3(2H)-one  | EC: 220-120-9<br>CAS: 2634-33-5<br>Index: 613-088-00-6           | <0.036  | Acute Tox. 4, H302<br>Acute Tox. 2, H330<br>Skin Irrit. 2, H315<br>Eye Dam. 1, H318<br>Skin Sens. 1A, H317<br>Aquatic Acute 1, H400<br>Aquatic Chronic 1, H410                                 | ATE [Oral] = 450 mg/kg<br>ATE [Inhalation (dusts and mists)] = 0.21 mg/l<br>Skin Sens. 1, H317: C ≥ 0.036%<br>M [Acute] = 1<br>M [Chronic] = 1  | [1]  |
| reaction mass of: 5-chloro-2-methyl-4-isothiazolin-3-one [EC no. 247-500-7] and 2-methyl-2H-isothiazol-3-one [EC no. 220-239-6] (3:1) | EC: 911-418-6<br>CAS: 55965-84-9<br>Index: 613-167-00-5          | <0.001  | Acute Tox. 3, H301<br>Acute Tox. 2, H310<br>Acute Tox. 2, H330<br>Skin Corr. 1C, H314<br>Eye Dam. 1, H318<br>Skin Sens. 1A, H317<br>Aquatic Acute 1, H400<br>Aquatic Chronic 1, H410<br>EUH071 | ATE [Oral] = 53 mg/kg<br>ATE [Dermal] = 50 mg/kg<br>ATE [Inhalation (vapours)] = 0.5 mg/l<br>Skin Corr. 1C, H314: C ≥ 0.6%<br>Eye Dam. 1, H318: C ≥ 0.6%<br>Eye Irrit. 2, H319: 0.06% ≤ C < 0.6%<br>Skin Sens. 1, H317: C ≥ 0.0015%<br>M [Acute] = 100<br>M [Chronic] = 100 | [1]  |
| 2-methyl-2H-isothiazol-3-one  | EC: 220-239-6<br>CAS: 2682-20-4<br>Index: 613-326-00-9           | <0.0015 | Acute Tox. 3, H301<br>Acute Tox. 3, H311<br>Acute Tox. 2, H330<br>Skin Corr. 1B, H314<br>Eye Dam. 1, H318<br>Skin Sens. 1A, H317<br>Aquatic Acute 1, H400<br>Aquatic Chronic 1, H410<br>EUH071 | ATE [Oral] = 100 mg/kg<br>ATE [Dermal] = 300 mg/kg<br>ATE [Inhalation (dusts and mists)] = 0.11 mg/l<br>Skin Sens. 1, H317: C ≥ 0.0015%<br>M [Acute] = 10<br>M [Chronic] = 1  | [1]  |
| 2-Octyl-2H-isothiazol-3-one   | EC: 247-761-7  | <0.001  | Acute Tox. 3, H301   | ATE [Oral] = 125  | [1]  |

## SECTION 3: Composition/information on ingredients

|  |  |  |  |  |  |
|--|--|--|--|--|--|
|  | CAS: 26530-20-1<br>Index: 613-112-00-5 |  | Acute Tox. 3, H311<br>Acute Tox. 2, H330<br>Skin Corr. 1, H314<br>Eye Dam. 1, H318<br>Skin Sens. 1A, H317<br>Aquatic Acute 1, H400<br>Aquatic Chronic 1, H410<br>EUH071<br><br><b>See Section 16 for the full text of the H statements declared above.</b> | mg/kg<br>ATE [Dermal] = 311 mg/kg<br>ATE [Inhalation (dusts and mists)] = 0.27 mg/l<br>Skin Sens. 1, H317: C ≥ 0.0015%<br>M [Acute] = 100<br>M [Chronic] = 100 |  |
|--|--|--|--|--|--|

There are no additional ingredients present which, within the current knowledge of the supplier and in the concentrations applicable, are classified as hazardous to health or the environment, are PBTs, vPvBs or Substances of equivalent concern, or have been assigned a workplace exposure limit and hence require reporting in this section.

### Type

[1] Substance classified with a health or environmental hazard

[2] Substance with a workplace exposure limit

Occupational exposure limits, if available, are listed in Section 8.

## SECTION 4: First aid measures

### 4.1 Description of first aid measures

- Eye contact** : Immediately flush eyes with plenty of water, occasionally lifting the upper and lower eyelids. Check for and remove any contact lenses. Get medical attention if irritation occurs.
- Inhalation** : Remove victim to fresh air and keep at rest in a position comfortable for breathing. Get medical attention if symptoms occur.
- Skin contact** : Flush contaminated skin with plenty of water. Remove contaminated clothing and shoes. Get medical attention if symptoms occur.
- Ingestion** : Wash out mouth with water. If material has been swallowed and the exposed person is conscious, give small quantities of water to drink. Do not induce vomiting unless directed to do so by medical personnel. Get medical attention if symptoms occur.
- Protection of first-aiders** : No action shall be taken involving any personal risk or without suitable training.

### 4.2 Most important symptoms and effects, both acute and delayed

#### Over-exposure signs/symptoms

- Eye contact** : No specific data.
- Inhalation** : No specific data.
- Skin contact** : No specific data.
- Ingestion** : No specific data.

### 4.3 Indication of any immediate medical attention and special treatment needed

- Notes to physician** : Treat symptomatically. Contact poison treatment specialist immediately if large quantities have been ingested or inhaled.
- Specific treatments** : No specific treatment.

## SECTION 5: Firefighting measures

### 5.1 Extinguishing media

- Suitable extinguishing media** : Use an extinguishing agent suitable for the surrounding fire.
- Unsuitable extinguishing media** : None known.

## SECTION 5: Firefighting measures

### 5.2 Special hazards arising from the substance or mixture

- Hazards from the substance or mixture** : In a fire or if heated, a pressure increase will occur and the container may burst.
- Hazardous combustion products** : Decomposition products may include the following materials:  
carbon dioxide  
carbon monoxide  
metal oxide/oxides

### 5.3 Advice for firefighters

- Special protective actions for fire-fighters** : Promptly isolate the scene by removing all persons from the vicinity of the incident if there is a fire. No action shall be taken involving any personal risk or without suitable training.
- Special protective equipment for fire-fighters** : Fire-fighters should wear appropriate protective equipment and self-contained breathing apparatus (SCBA) with a full face-piece operated in positive pressure mode. Clothing for fire-fighters (including helmets, protective boots and gloves) conforming to European standard EN 469 will provide a basic level of protection for chemical incidents.

## SECTION 6: Accidental release measures



### 6.1 Personal precautions, protective equipment and emergency procedures

- For non-emergency personnel** : No action shall be taken involving any personal risk or without suitable training. Evacuate surrounding areas. Keep unnecessary and unprotected personnel from entering. Do not touch or walk through spilt material. Put on appropriate personal protective equipment.
- For emergency responders** : If specialised clothing is required to deal with the spillage, take note of any information in Section 8 on suitable and unsuitable materials. See also the information in "For non-emergency personnel".

### 6.2 Environmental precautions

- : Avoid dispersal of spilt material and runoff and contact with soil, waterways, drains and sewers. Inform the relevant authorities if the product has caused environmental pollution (sewers, waterways, soil or air).

### 6.3 Methods and material for containment and cleaning up

- Small spill** :  Stop leak if without risk. Move containers from spill area. Absorb with an inert material and place in an appropriate waste disposal container. Dispose of via a licensed waste disposal contractor.
- Large spill** :  Stop leak if without risk. Move containers from spill area. Prevent entry into sewers, water courses, basements or confined areas. Wash spillages into an effluent treatment plant or proceed as follows. Dispose of via a licensed waste disposal contractor. Contain and collect spillage with non-combustible, absorbent material e. g. sand, earth, vermiculite or diatomaceous earth and place in container for disposal according to local regulations.

### 6.4 Reference to other sections

- : See Section 1 for emergency contact information.  
See Section 8 for information on appropriate personal protective equipment.  
See Section 13 for additional waste treatment information.

## SECTION 7: Handling and storage

The information in this section contains generic advice and guidance. The list of Identified Uses in Section 1 should be consulted for any available use-specific information provided in the Exposure Scenario(s).

### 7.1 Precautions for safe handling

- Protective measures** : Put on appropriate personal protective equipment (see Section 8).
- Advice on general occupational hygiene** : Eating, drinking and smoking should be prohibited in areas where this material is handled, stored and processed. Workers should wash hands and face before eating, drinking and smoking. Remove contaminated clothing and protective equipment before entering eating areas. See also Section 8 for additional information on hygiene measures.

## SECTION 7: Handling and storage

### 7.2 Conditions for safe storage, including any incompatibilities

Store in accordance with local regulations. Store in original container protected from direct sunlight in a dry, cool and well-ventilated area, away from incompatible materials (see Section 10) and food and drink. Keep container tightly closed and sealed until ready for use. Containers that have been opened must be carefully resealed and kept upright to prevent leakage. Do not store in unlabelled containers. Use appropriate containment to avoid environmental contamination. See Section 10 for incompatible materials before handling or use.

### 7.3 Specific end use(s)

**Recommendations** : Not available.

**Industrial sector specific solutions** : Not available.

## SECTION 8: Exposure controls/personal protection

The information in this section contains generic advice and guidance. Information is provided based on typical anticipated uses of the product. Additional measures might be required for bulk handling or other uses that could significantly increase worker exposure or environmental releases.

### 8.1 Control parameters

#### Occupational exposure limits

| Product/ingredient name      | Exposure limit values   |
|------------------------------|---|
| Dipropyleneglycolmethylether | <b>EU OEL (Europe, 1/2022) [(2-Methoxymethylethoxy)-propanol]</b><br>Absorbed through skin.<br>TWA 8 hours: 50 ppm.<br>TWA 8 hours: 308 mg/m <sup>3</sup> . |

#### Biological exposure indices

| Product/ingredient name    | Exposure indices |
|----------------------------|------------------|
| No exposure indices known. |                  |

**Recommended monitoring procedures** : Reference should be made to monitoring standards, such as the following: European Standard EN 689 (Workplace atmospheres - Guidance for the assessment of exposure by inhalation to chemical agents for comparison with limit values and measurement strategy) European Standard EN 14042 (Workplace atmospheres - Guide for the application and use of procedures for the assessment of exposure to chemical and biological agents) European Standard EN 482 (Workplace atmospheres - General requirements for the performance of procedures for the measurement of chemical agents) Reference to national guidance documents for methods for the determination of hazardous substances will also be required.

#### DNELs/DMELs

| Product/ingredient name      | Result   |
|------------------------------|--|
| Dipropyleneglycolmethylether | <b>DNEL - General population - Long term - Oral</b><br>36 mg/kg bw/day<br><u>Effects</u> : Systemic<br><br><b>DNEL - General population - Long term - Inhalation</b><br>37.2 mg/m <sup>3</sup><br><u>Effects</u> : Systemic<br><br><b>DNEL - General population - Long term - Dermal</b><br>121 mg/kg bw/day<br><u>Effects</u> : Systemic<br><br><b>DNEL - Workers - Long term - Dermal</b><br>283 mg/kg bw/day<br><u>Effects</u> : Systemic<br><br><b>DNEL - Workers - Long term - Inhalation</b><br>308 mg/m <sup>3</sup><br><u>Effects</u> : Systemic |

## SECTION 8: Exposure controls/personal protection

adipohydrazide

**DNEL - Workers - Long term - Inhalation**

17.5 mg/m<sup>3</sup>

Effects: Systemic

1,2-benzisothiazol-3(2H)-one

**DNEL - General population - Long term - Dermal**

0.345 mg/kg bw/day

Effects: Systemic

**DNEL - Workers - Long term - Dermal**

0.966 mg/kg bw/day

Effects: Systemic

**DNEL - General population - Long term - Inhalation**

1.2 mg/m<sup>3</sup>

Effects: Systemic

**DNEL - Workers - Long term - Inhalation**

6.81 mg/m<sup>3</sup>

Effects: Systemic

reaction mass of: 5-chloro-2-methyl-4-isothiazolin-3-one [EC no. 247-500-7] and 2-methyl-2H-isothiazol-3-one [EC no. 220-239-6] (3:1)

**DNEL - General population - Long term - Inhalation**

0.02 mg/m<sup>3</sup>

Effects: Local

**DNEL - Workers - Long term - Inhalation**

0.02 mg/m<sup>3</sup>

Effects: Local

**DNEL - General population - Short term - Inhalation**

0.04 mg/m<sup>3</sup>

Effects: Local

**DNEL - Workers - Short term - Inhalation**

0.04 mg/m<sup>3</sup>

Effects: Local

**DNEL - General population - Long term - Oral**

0.09 mg/kg bw/day

Effects: Systemic

**DNEL - General population - Short term - Oral**

0.11 mg/kg bw/day

Effects: Systemic

2-methyl-2H-isothiazol-3-one

**DNEL - General population - Long term - Inhalation**

0.021 mg/m<sup>3</sup>

Effects: Local

**DNEL - Workers - Long term - Inhalation**

0.021 mg/m<sup>3</sup>

Effects: Local

**DNEL - General population - Long term - Oral**

0.027 mg/kg bw/day

Effects: Systemic

**DNEL - General population - Short term - Inhalation**

0.043 mg/m<sup>3</sup>

Effects: Local

**DNEL - Workers - Short term - Inhalation**

0.043 mg/m<sup>3</sup>

Effects: Local

**DNEL - General population - Short term - Oral**

## SECTION 8: Exposure controls/personal protection

0.053 mg/kg bw/day

Effects: Systemic

### PNECs

Not available.

### 8.2 Exposure controls

**Appropriate engineering controls** : Good general ventilation should be sufficient to control worker exposure to airborne contaminants.

#### Individual protection measures

**Hygiene measures** : Wash hands, forearms and face thoroughly after handling chemical products, before eating, smoking and using the lavatory and at the end of the working period. Appropriate techniques should be used to remove potentially contaminated clothing. Wash contaminated clothing before reusing. Ensure that eyewash stations and safety showers are close to the workstation location.

**Eye/face protection** : Safety eyewear complying with an approved standard should be used when a risk assessment indicates this is necessary to avoid exposure to liquid splashes, mists, gases or dusts. If contact is possible, the following protection should be worn, unless the assessment indicates a higher degree of protection: safety glasses with side-shields.

#### Skin protection

**Hand protection** : Chemical-resistant, impervious gloves complying with an approved standard should be worn at all times when handling chemical products if a risk assessment indicates this is necessary.

Recommendations : Wear suitable gloves tested to EN374.

> 8 hours (breakthrough time): Nitrile gloves. thickness > 0.3 mm

Not recommended polyvinyl alcohol (PVA) gloves

**Body protection** : Personal protective equipment for the body should be selected based on the task being performed and the risks involved and should be approved by a specialist before handling this product.

**Other skin protection** : Appropriate footwear and any additional skin protection measures should be selected based on the task being performed and the risks involved and should be approved by a specialist before handling this product.

**Respiratory protection** : Based on the hazard and potential for exposure, select a respirator that meets the appropriate standard or certification. Respirators must be used according to a respiratory protection program to ensure proper fitting, training, and other important aspects of use.

Filter type (spray application): A P

**Environmental exposure controls** : Emissions from ventilation or work process equipment should be checked to ensure they comply with the requirements of environmental protection legislation. In some cases, fume scrubbers, filters or engineering modifications to the process equipment will be necessary to reduce emissions to acceptable levels.

## SECTION 9: Physical and chemical properties

The conditions of measurement of all properties are at standard temperature and pressure unless otherwise indicated.

### 9.1 Information on basic physical and chemical properties

#### Appearance

**Physical state** : Liquid.

**Colour** : Clear.

**Odour** : Slight

**Odour threshold** : Not available.

**Melting point/freezing point** : Not available.

**Initial boiling point and boiling range** :



## SECTION 9: Physical and chemical properties

| Ingredient name              | °C    | °F    | Method |
|------------------------------|-------|-------|--------|
| water                        | 100   | 212   |        |
| Dipropyleneglycolmethylether | 189.6 | 373.3 | EU A.2 |

**Flammability** : Not available.  
**Lower and upper explosion limit** : Lower: Not applicable.  
Upper: Not applicable.  
**Flash point** : Closed cup: >100°C (>212°F)  
**Auto-ignition temperature** :

| Ingredient name              | °C  | °F    | Method  |
|------------------------------|-----|-------|---------|
| Dipropyleneglycolmethylether | 207 | 404.6 | EU A.15 |

**Decomposition temperature** : Not available.  
**pH** : 8 to 8.5 [Conc. (% w/w): 100%]  
**Viscosity** : Not available.  
**Solubility(ies)** :  
Not available.

**Solubility in water** : Not available.  
**Partition coefficient: n-octanol/ water** : Not applicable.  
**Vapour pressure** :

| Ingredient name | Vapour Pressure at 20°C |     |        | Vapour pressure at 50°C |     |        |
|-----------------|-------------------------|-----|--------|-------------------------|-----|--------|
|                 | mm Hg                   | kPa | Method | mm Hg                   | kPa | Method |
| water           | 17.5                    | 2.3 |        |                         |     |        |

**Relative density** : Not available.  
**Density** : 1 g/cm<sup>3</sup>  
**Vapour density** : Not available.  
**Particle characteristics**  
**Median particle size** : Not applicable.

### 9.2 Other information

#### 9.2.1 Information with regard to physical hazard classes

**Explosive properties** : Not available.  
**Oxidising properties** : Not available.

#### 9.2.2 Other safety characteristics

Not applicable.

## SECTION 10: Stability and reactivity

**10.1 Reactivity** : No specific test data related to reactivity available for this product or its ingredients.

**10.2 Chemical stability** : The product is stable.

**10.3 Possibility of hazardous reactions** : Under normal conditions of storage and use, hazardous reactions will not occur.

**10.4 Conditions to avoid** : No specific data.

**10.5 Incompatible materials** : No specific data.



## SECTION 10: Stability and reactivity

**10.6 Hazardous decomposition products** : Under normal conditions of storage and use, hazardous decomposition products should not be produced.

## SECTION 11: Toxicological information

### 11.1 Information on hazard classes as defined in Regulation (EC) No 1272/2008

#### Acute toxicity

##### Product/ingredient name

1,2-benzisothiazol-3(2H)-one

reaction mass of: 5-chloro-2-methyl-4-isothiazolin-3-one [EC no. 247-500-7] and 2-methyl-2H-isothiazol-3-one [EC no. 220-239-6] (3:1)

2-methyl-2H-isothiazol-3-one

2-Octyl-2H-isothiazol-3-one

##### Result

**Rat - Oral - LD50**  
1020 mg/kg

**Rat - Oral - LD50**  
53 mg/kg  
Toxic effects: Behavioral - Somnolence (general depressed activity) Behavioral - Ataxia Lung, Thorax, or Respiration - Respiratory depression

**Rat - Inhalation - LC50 Dusts and mists**  
0.11 mg/l [4 hours]

**Rat - Oral - LD50**  
550 mg/kg  
  
**Rabbit - Dermal - LD50**  
690 mg/kg

**Conclusion/Summary [Product]** : Not available.

#### Acute toxicity estimates

| Product/ingredient name   | Oral (mg/kg) | Dermal (mg/kg) | Inhalation (gases) (ppm) | Inhalation (vapours) (mg/l) | Inhalation (dusts and mists) (mg/l) |
|---|--------------|----------------|--------------------------|-----------------------------|-------------------------------------|
| 1,2-benzisothiazol-3(2H)-one  | N/A          | N/A            | N/A                      | 1745.5                      | N/A                                 |
| reaction mass of: 5-chloro-2-methyl-4-isothiazolin-3-one [EC no. 247-500-7] and 2-methyl-2H-isothiazol-3-one [EC no. 220-239-6] (3:1) | 450          | N/A            | N/A                      | N/A                         | 0.21                                |
| 2-methyl-2H-isothiazol-3-one  | 53           | 50             | N/A                      | 0.5                         | N/A                                 |
| 2-methyl-2H-isothiazol-3-one  | 100          | 300            | N/A                      | N/A                         | 0.11                                |
| 2-Octyl-2H-isothiazol-3-one   | 125          | 311            | N/A                      | N/A                         | 0.27                                |

#### Skin corrosion/irritation

##### Product/ingredient name

Dipropyleneglycolmethylether

1,2-benzisothiazol-3(2H)-one

reaction mass of: 5-chloro-2-methyl-4-isothiazolin-3-one [EC no. 247-500-7] and 2-methyl-2H-isothiazol-3-one [EC no. 220-239-6] (3:1)

##### Result

**Rabbit - Skin - Mild irritant**  
Amount/concentration applied: 500 mg

**Human - Skin - Mild irritant**  
Duration of treatment/exposure: 48 hours  
Amount/concentration applied: 5 %

**Human - Skin - Severe irritant**  
Amount/concentration applied: 0.01 %

**Conclusion/Summary [Product]** : Not available.

#### Serious eye damage/eye irritation

##### Product/ingredient name

##### Result

## SECTION 11: Toxicological information

Dipropyleneglycolmethylether

**Human - Eyes - Mild irritant**

Amount/concentration applied: 8 mg

**Rabbit - Eyes - Mild irritant**

Duration of treatment/exposure: 24 hours

Amount/concentration applied: 500 mg

2-Octyl-2H-isothiazol-3-one

**Rabbit - Eyes - Severe irritant**

Amount/concentration applied: 100 mg

**Conclusion/Summary [Product]** : Not available.

### Respiratory corrosion/irritation

Not available.

**Conclusion/Summary [Product]** : Not available.

### Respiratory or skin sensitization

Not available.

### Skin

**Conclusion/Summary [Product]** : Not available.

### Respiratory

**Conclusion/Summary [Product]** : Not available.

### Germ cell mutagenicity

Not available.

**Conclusion/Summary [Product]** : Not available.

### Carcinogenicity

Not available.

**Conclusion/Summary [Product]** : Not available.

### Reproductive toxicity

Not available.

**Conclusion/Summary [Product]** : Not available.

### Specific target organ toxicity (single exposure)

Not available.

### Specific target organ toxicity (repeated exposure)

Not available.

### Aspiration hazard

Not available.

### Information on likely routes of exposure

Not available.

### Potential acute health effects

**Eye contact** : No known significant effects or critical hazards.

## SECTION 11: Toxicological information

**Inhalation** : No known significant effects or critical hazards.

**Skin contact** : No known significant effects or critical hazards.

**Ingestion** : No known significant effects or critical hazards.

### Symptoms related to the physical, chemical and toxicological characteristics

**Eye contact** : No specific data.

**Inhalation** : No specific data.

**Skin contact** : No specific data.

**Ingestion** : No specific data.

### Delayed and immediate effects as well as chronic effects from short and long-term exposure

#### Short term exposure

**Potential immediate effects** : Not available.

**Potential delayed effects** : Not available.

#### Long term exposure

**Potential immediate effects** : Not available.

**Potential delayed effects** : Not available.

### Potential chronic health effects

Not available.

**Conclusion/Summary [Product]** : Not available.

**General** : No known significant effects or critical hazards.

**Carcinogenicity** : No known significant effects or critical hazards.

**Mutagenicity** : No known significant effects or critical hazards.

**Reproductive toxicity** : No known significant effects or critical hazards.

## 11.2 Information on other hazards

### 11.2.1 Endocrine disrupting properties

Not available.

**Conclusion/Summary [Product]** : The product does not meet the criteria to be considered as having endocrine disrupting properties according to the criteria set out in either Regulation (EC) No. 1907/2006 or Regulation (EC) No 1272/2008.

### 11.2.2 Other information

Not available.

## SECTION 12: Ecological information

### 12.1 Toxicity

#### **Product/ingredient name**

2,2-benzisothiazol-3(2H)-one

#### **Result**

##### **Acute - LC50 - Fresh water**

OECD [Fish, Acute Toxicity Test]

Fish - Trout - *Onorhynchus Mykiss*

1.9 mg/l [96 hours]

##### **Acute - EC50**

OECD 202 [Daphnia sp. Acute Immobilization Test and Reproduction Test]

Daphnia - Daphnia - *Daphnia Magna*

3.7 mg/l [48 hours]

##### **Acute - EC50 - Marine water**

OECD 201 [Alga, Growth Inhibition Test]

Algae - Algae - *Skeletonema Costatum*

0.36 mg/l [72 hours]

##### **Acute - NOEC - Marine water**

OECD 201 [Alga, Growth Inhibition Test]

Algae - Algae - *Skeletonema Costatum*



## SECTION 12: Ecological information

### Soil/water partition coefficient

| Product/ingredient name      | logKoc | Koc     |
|------------------------------|--------|---------|
| adipohydrazide               | 1.7    | 55.2165 |
| 1,2-benzisothiazol-3(2H)-one | 1.9    | 73.142  |
| 2-methyl-2H-isothiazol-3-one | 1.7    | 54.9187 |
| 2-Octyl-2H-isothiazol-3-one  | 2.8    | 706.605 |

### Results of PMT and vPvM assessment

| Product/ingredient name   | PMT | P  | M  | T  | vPvM | vP | vM |
|---|-----|----|----|----|------|----|----|
| Dipropyleneglycolmethylether  | No  | No | No | No | No   | No | No |
| adipohydrazide  | No  | No | No | No | No   | No | No |
| 1,2-benzisothiazol-3(2H)-one  | No  | No | No | No | No   | No | No |
| reaction mass of: 5-chloro-2-methyl-4-isothiazolin-3-one [EC no. 247-500-7] and 2-methyl-2H-isothiazol-3-one [EC no. 220-239-6] (3:1) | No  | No | No | No | No   | No | No |
| 2-methyl-2H-isothiazol-3-one  | No  | No | No | No | No   | No | No |
| 2-Octyl-2H-isothiazol-3-one   | No  | No | No | No | No   | No | No |

**Mobility** : Not available.

**Conclusion/Summary** : The product does not meet the criteria to be considered as a PMT or vPvM.

### 12.5 Results of PBT and vPvB assessment

#### Regulation (EC) No. 1907/2006 [REACH]

| Product/ingredient name   | PBT | P   | B   | T   | vPvB | vP  | vB  |
|---|-----|-----|-----|-----|------|-----|-----|
| Dipropyleneglycolmethylether  | No  | N/A | N/A | No  | N/A  | N/A | N/A |
| adipohydrazide  | No  | N/A | N/A | No  | N/A  | N/A | N/A |
| 1,2-benzisothiazol-3(2H)-one  | No  | N/A | No  | No  | No   | N/A | No  |
| reaction mass of: 5-chloro-2-methyl-4-isothiazolin-3-one [EC no. 247-500-7] and 2-methyl-2H-isothiazol-3-one [EC no. 220-239-6] (3:1) | No  | N/A | N/A | No  | N/A  | N/A | N/A |
| 2-methyl-2H-isothiazol-3-one  | No  | N/A | N/A | No  | N/A  | N/A | N/A |
| 2-Octyl-2H-isothiazol-3-one   | N/A | N/A | N/A | Yes | N/A  | N/A | N/A |

#### Regulation (EC) No. 1272/2008 [CLP]

| Product/ingredient name   | PBT | P  | B  | T  | vPvB | vP | vB |
|---|-----|----|----|----|------|----|----|
| Dipropyleneglycolmethylether  | No  | No | No | No | No   | No | No |
| adipohydrazide  | No  | No | No | No | No   | No | No |
| 1,2-benzisothiazol-3(2H)-one  | No  | No | No | No | No   | No | No |
| reaction mass of: 5-chloro-2-methyl-4-isothiazolin-3-one [EC no. 247-500-7] and 2-methyl-2H-isothiazol-3-one [EC no. 220-239-6] (3:1) | No  | No | No | No | No   | No | No |
| 2-methyl-2H-isothiazol-3-one  | No  | No | No | No | No   | No | No |
| 2-Octyl-2H-isothiazol-3-one   | No  | No | No | No | No   | No | No |

**Conclusion/Summary** : The product does not meet the criteria to be considered as a PBT or vPvB.

#### Regulation (EC) No. 1272/2008 [CLP]

### 12.6 Endocrine disrupting properties

Not available.

## SECTION 12: Ecological information

**Conclusion/Summary [Product]** : The product does not meet the criteria to be considered as having endocrine disrupting properties according to the criteria set out in either Regulation (EC) No. 1907/2006 or Regulation (EC) No 1272/2008.

### 12.7 Other adverse effects

No known significant effects or critical hazards.

## SECTION 13: Disposal considerations

### 13.1 Waste treatment methods

#### Product

**Methods of disposal** : The generation of waste should be avoided or minimised wherever possible. Disposal of this product, solutions and any by-products should at all times comply with the requirements of environmental protection and waste disposal legislation and any regional local authority requirements. Dispose of surplus and non-recyclable products via a licensed waste disposal contractor. Waste should not be disposed of untreated to the sewer unless fully compliant with the requirements of all authorities with jurisdiction.

**Hazardous waste** : Within the present knowledge of the supplier, this product is not regarded as hazardous waste, as defined by EU Directive 2008/98/EC.

**European waste catalogue (EWC)** : 080112

#### Packaging

**Methods of disposal** : The generation of waste should be avoided or minimised wherever possible. Waste packaging should be recycled. Incineration or landfill should only be considered when recycling is not feasible.

**Special precautions** : This material and its container must be disposed of in a safe way. Empty containers or liners may retain some product residues. Avoid dispersal of spilt material and runoff and contact with soil, waterways, drains and sewers.

## SECTION 14: Transport information

|                                 | ADR/RID        | ADN            | IMDG           | IATA           |
|---------------------------------|----------------|----------------|----------------|----------------|
| 14.1 UN number or ID number     | Not regulated. | Not regulated. | Not regulated. | Not regulated. |
| 14.2 UN proper shipping name    | -              | -              | -              | -              |
| 14.3 Transport hazard class(es) | -              | -              | -              | -              |
| 14.4 Packing group              | -              | -              | -              | -              |
| 14.5 Environmental hazards      | No.            | No.            | No.            | No.            |

**14.6 Special precautions for user** : **Transport within user's premises:** always transport in closed containers that are upright and secure. Ensure that persons transporting the product know what to do in the event of an accident or spillage.

**14.7 Maritime transport in bulk according to IMO instruments** : Not relevant/applicable due to nature of the product.

## SECTION 15: Regulatory information

### 15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

#### EU Regulation (EC) No. 1907/2006 (REACH)

##### Annex XIV - List of substances subject to authorisation

###### Annex XIV

None of the components are listed.

###### Substances of very high concern

None of the components are listed.

#### Annex XVII - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, mixtures and articles

Labelling :

##### Other EU regulations

Industrial emissions  
(integrated pollution  
prevention and control) -  
Air : Not listed

Industrial emissions  
(integrated pollution  
prevention and control) -  
Water : Not listed

Explosive precursors : Not applicable.

##### Ozone depleting substances (EU 2024/590)

Not listed.

##### Prior Informed Consent (PIC) (649/2012/EU)

Not listed.

##### Persistent Organic Pollutants

Not listed.

##### Seveso Directive

This product is not controlled under the Seveso Directive.

##### International regulations

##### Chemical Weapon Convention List Schedules I, II & III Chemicals

Not listed.

##### Montreal Protocol

Not listed.

##### Stockholm Convention on Persistent Organic Pollutants

Not listed.

##### Rotterdam Convention on Prior Informed Consent (PIC)

Not listed.

##### UNECE Aarhus Protocol on POPs and Heavy Metals

Not listed.

**15.2 Chemical safety assessment** : This product contains substances for which Chemical Safety Assessments are still required.



## SECTION 16: Other information

Indicates information that has changed from previously issued version.

### Abbreviations and acronyms

: ATE = Acute Toxicity Estimate  
CLP = Classification, Labelling and Packaging Regulation [Regulation (EC) No. 1272/2008]  
DMEL = Derived Minimal Effect Level  
DNEL = Derived No Effect Level  
EUH statement = CLP-specific Hazard statement  
N/A = Not available  
PBT = Persistent, Bioaccumulative and Toxic  
PNEC = Predicted No Effect Concentration  
RRN = REACH Registration Number  
SGG = Segregation Group  
vPvB = Very Persistent and Very Bioaccumulative

### Procedure used to derive the classification according to Regulation (EC) No. 1272/2008 [CLP/GHS]

Not classified.

### Full text of abbreviated H statements

|        |   |
|--------|---|
| H301   | Toxic if swallowed.                                   |
| H302   | Harmful if swallowed.                                 |
| H310   | Fatal in contact with skin.                           |
| H311   | Toxic in contact with skin.                           |
| H314   | Causes severe skin burns and eye damage.              |
| H315   | Causes skin irritation.                               |
| H317   | May cause an allergic skin reaction.                  |
| H318   | Causes serious eye damage.                            |
| H330   | Fatal if inhaled.                                     |
| H400   | Very toxic to aquatic life.                           |
| H410   | Very toxic to aquatic life with long lasting effects. |
| H411   | Toxic to aquatic life with long lasting effects.      |
| EUH071 | Corrosive to the respiratory tract.                   |

### Full text of classifications [CLP/GHS]

|                   |   |
|-------------------|---|
| Acute Tox. 2      | ACUTE TOXICITY - Category 2                     |
| Acute Tox. 3      | ACUTE TOXICITY - Category 3                     |
| Acute Tox. 4      | ACUTE TOXICITY - Category 4                     |
| Aquatic Acute 1   | SHORT-TERM (ACUTE) AQUATIC HAZARD - Category 1  |
| Aquatic Chronic 1 | LONG-TERM (CHRONIC) AQUATIC HAZARD - Category 1 |
| Aquatic Chronic 2 | LONG-TERM (CHRONIC) AQUATIC HAZARD - Category 2 |
| Eye Dam. 1        | SERIOUS EYE DAMAGE/EYE IRRITATION - Category 1  |
| Skin Corr. 1      | SKIN CORROSION/IRRITATION - Category 1          |
| Skin Corr. 1B     | SKIN CORROSION/IRRITATION - Category 1B         |
| Skin Corr. 1C     | SKIN CORROSION/IRRITATION - Category 1C         |
| Skin Irrit. 2     | SKIN CORROSION/IRRITATION - Category 2          |
| Skin Sens. 1      | SKIN SENSITISATION - Category 1                 |
| Skin Sens. 1A     | SKIN SENSITISATION - Category 1A                |

**Date of issue/ Date of revision** : 04/07/2025

**Date of previous issue** : 26/10/2023

**Version** : 2

AQUATOP 2600-82\_BASE 3

BASE 3

### Notice to reader

The information in this SDS is based on the present state of our knowledge and on current laws. The product is not to be used for purposes other than those specified under section 1 without first obtaining written handling instructions. It is always the responsibility of the user to take all necessary steps to fulfil the demands set out in the local rules and legislation. The information in this SDS is meant to be a description of the safety requirements for our product. It is not to be considered a guarantee of the product's properties.

